1. Home
  2. CRT vs MAIA Comparison

CRT vs MAIA Comparison

Compare CRT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cross Timbers Royalty Trust

CRT

Cross Timbers Royalty Trust

HOLD

Current Price

$10.85

Market Cap

63.2M

Sector

Energy

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.34

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRT
MAIA
Founded
1991
2018
Country
United States
United States
Employees
2
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.2M
77.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CRT
MAIA
Price
$10.85
$1.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.8K
851.6K
Earning Date
04-14-2026
05-12-2026
Dividend Yield
5.29%
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.07
$0.87
52 Week High
$11.10
$3.19

Technical Indicators

Market Signals
Indicator
CRT
MAIA
Relative Strength Index (RSI) 51.06 49.86
Support Level $10.15 $1.21
Resistance Level $11.08 $1.46
Average True Range (ATR) 0.31 0.10
MACD -0.01 0.02
Stochastic Oscillator 60.00 35.29

Price Performance

Historical Comparison
CRT
MAIA

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: